Abstract 10340: Higher Prevalance of Non-Group 1 Pulmonary Hypertension in Admissions Among Cancer Survivors with Worse In-Hospital Outcomes- A Nationwide Analysis

Abstract

Introduction: Pulmonary hypertension (PH) in cancer patients is an underrecognized problem. It can be secondary to malignancy, medications, thromboemboli in lung, and underlying cardiac or lung disease. Outcomes of PH in cancer survivors have not been studied before. The objective of this study is to study the prevalence and impact of Non-group 1 PH on admissions among cancer survivors. Methods: The National Inpatient Sample (October, 2015 to 2017), was used to identify all adult hospitalizations among cancer survivors with PH using ICD-10 codes. Primary outcome were prevalence and demographics of PH in cancer survivors. Secondary outcomes were in-hospital mortality and healthcare resource utilization. Results: Of 6,003,538 weighted nationwide admissions of cancer survivors, 4.7% (282,810) had non-group 1 PH. The prevalence of PH was higher in patients with prior cancers compared to other admissions (4.7% vs. 3.3%, p<0.001). It was higher in females than males (5.1% vs. 4.3%). Most common in blacks (5.9%), followed by whites (4.7%), Native American (4.1%), Asian or Pacific Islander (3.8%), others (3.7%) and Hispanics (3.3%) (Fig. 1) . Hypertension, Diabetes, smoking, obesity, renal failure, congestive heart failure, valvular heart disease and chronic pulmonary disease were higher in PH group. In-hospital outcomes in cancer survivors with vs. without PH showed significantly higher all-cause inpatient mortality in PH group (OR1.34, 95% CI=1.31-1.37, p<0.001) with fewer routine discharges (39.3% vs. 52.1%, p<0.001), higher transfer rate to short-term hospital, and other facilities (skilled nursing care/intermediate care facility), higher home health care requirement, prolonged hospital stay (4 vs 3 days), and higher cost ($10,325 vs. $9163) per admission. Conclusion: This is the first large-scale study to demonstrate the higher burden and worse in-hospital outcomes of non-group 1 PH in cancer survivors. Early diagnosis and treatment is necessary.